# Phase II Clinical Study of HDM1005 Injection in Obese Adults Without Diabetes Mellitus

> **NCT06886126** · PHASE2 · RECRUITING · sponsor: **Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.** · enrollment: 240 (estimated)

## Conditions studied

- Obesity

## Interventions

- **DRUG:** HDM1005 injection or placebo

## Key facts

- **NCT ID:** NCT06886126
- **Lead sponsor:** Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-07
- **Primary completion:** 2025-09-23
- **Final completion:** 2025-11-30
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2025-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06886126

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06886126, "Phase II Clinical Study of HDM1005 Injection in Obese Adults Without Diabetes Mellitus". Retrieved via AI Analytics 2026-09-17 from https://api.ai-analytics.org/clinical/NCT06886126. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*